Clinical Trial: JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07582822) titled 'JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC' on April 29.

Brief Summary: This is an open-label, multicenter Phase I study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of JH021 injection in patients with advanced solid tumors. JH021 is a bispecific monoclonal antibody targeting EGFR and cMET. The study will assess JH021 in patients with advanced solid tumors for whom standard therapy is unavailable, intolerable, or no longer effective, and will provide data to support further clinical development.

Study Start Date: May 30

Study Type: INTERVEN...